Therapy: Rheumatic disease after immune checkpoint inhibitor therapy

被引：0
|
作者：
Ummarino D.
机构：
来源：
Nature Reviews Rheumatology | 2017年 / 13卷 / 8期
关键词：
D O I：
10.1038/nrrheum.2017.113
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：450 / 450
相关论文
共 50 条
  • [41] Neurotoxicities associated with immune checkpoint inhibitor therapy
    Sophie L. Duong
    Frank J. Barbiero
    Richard J. Nowak
    Joachim M. Baehring
    Journal of Neuro-Oncology, 2021, 152 : 265 - 277
  • [42] Progress in Immune Checkpoint Inhibitor for Melanoma Therapy
    Boutros, Celine
    Herrscher, Hugo
    Robert, Caroline
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (05) : 997 - 1010
  • [43] Insights on Immune Checkpoint Inhibitor Therapy Toxicity
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 272 - 272
  • [44] Predictive markers for immune checkpoint inhibitor therapy
    Wiesweg, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 12 - 12
  • [45] Neurotoxicities Associated with Immune Checkpoint Inhibitor Therapy
    Duong, Sophie L.
    Barbiero, Frank J.
    Nowak, Richard J.
    Baehring, Joachim M.
    ANNALS OF NEUROLOGY, 2018, 84 : S138 - S138
  • [46] Immune Checkpoint Inhibitor Therapy in Breast Cancer
    Santa-Maria, Cesar A.
    Nanda, Rita
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (10): : 1259 - 1268
  • [47] Interstitial nephritis in immune checkpoint inhibitor therapy
    Manohar, Sandhya
    Albright, Robert C., Jr.
    KIDNEY INTERNATIONAL, 2019, 96 (01) : 252 - 252
  • [48] Toxicity in the era of immune checkpoint inhibitor therapy
    Keam, Synat
    Turner, Naimah
    Kugeratski, Fernanda G.
    Rico, Rene
    Colunga-Minutti, Jocelynn
    Poojary, Rayansh
    Alekseev, Sayan
    Patel, Anisha B.
    Li, Yuanteng Jeff
    Sheshadri, Ajay
    Loghin, Monica E.
    Woodman, Karin
    Aaroe, Ashley E.
    Hamidi, Sarah
    Iyer, Priyanka Chandrasekhar
    Palaskas, Nicolas L.
    Wang, Yinghong
    Nurieva, Roza
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [49] Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.
    Abu-Sbeih, Hamzah
    Ali, Faisal
    Naqash, Abdul Rafeh
    Owen, Dwight Hall
    Patel, Sandip H.
    Otterson, Gregory Alan
    Kendra, Kari Lynn
    Ricciuti, Biagio
    Chiari, Rita
    De Giglio, Andrea
    Sleiman, Joseph
    Funchain, Pauline
    Beatriz, Wills
    Zhang, Jiajia
    Naidoo, Jarushka
    Philpott, Jessica
    Gao, Jianjun
    Subudhi, Sumit Kumar
    Wang, Yinghong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know
    Camelliti, Simone
    Le Noci, Valentino
    Bianchi, Francesca
    Moscheni, Claudia
    Arnaboldi, Francesca
    Gagliano, Nicoletta
    Balsari, Andrea
    Garassino, Marina Chiara
    Tagliabue, Elda
    Sfondrini, Lucia
    Sommariva, Michele
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
12345